Quick Answer
MiNK Therapeutics, Inc. reported Total Assets of $14.24 million for the year ending 2025.
- MiNK Therapeutics, Inc. showed an increase of +148.9% in Total Assets from 2024 to 2025.
- This data is from MiNK Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: $4.08 million | Q1 2022: $36.14 million | Q2 2022: $31.12 million | Q3 2022: $25.26 million | Q1 2023: $16.59 million | Q2 2023: $12.11 million | Q3 2023: $7.46 million | Q1 2024: $6.89 million | Q2 2024: $10.32 million | Q3 2024: $7.37 million | Q1 2025: $4.27 million | Q2 2025: $2.48 million | Q3 2025: $14.96 million.
- Over the full 6 years of available data (2020 to 2025), MiNK Therapeutics, Inc.'s Total Assets has grown by 212.6%.
- Historical annual values: Fiscal year 2025: $14.24 million | Fiscal year 2024: $5.72 million | Fiscal year 2023: $4.55 million | Fiscal year 2022: $21.47 million | Fiscal year 2021: $40.24 million | Fiscal year 2020: $4.56 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: